Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a nasal spray slow Alzheimer's? new trial aims to find out

NCT ID NCT07178678

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial will test whether a nasal spray called NeuroEPO can help maintain thinking and memory in people with mild to moderate Alzheimer's disease. About 90 adults aged 50 and older will receive either NeuroEPO or a placebo three times a week for one year. Researchers will measure changes in cognitive function and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NeuroEPO (a form of erythropoietin given as a nasal spray)
What this could lead to
If it works, this could point toward a new way to slow memory loss and thinking problems in people with early-to-moderate Alzheimer's disease.
What could go wrong
This is a small, early-phase trial (90 people) testing a drug that has not been proven effective for Alzheimer's. It may show no benefit or cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients \>= 50 years of age, to reflect the population that will be treated and to avoid younger populations who may be suffering dementia from a cause other than Alzheimer's Disease. * Patients with Global Deterioration Scale (GDS) between 3 to 5 points (inclusive). * Clinical Dementia Rating (CDR) - GS score 1-2 at screening. * Patients with permeable airways. * Patients (or caregiver, if the patient cannot) grant consent to participate in the study by signing the informed consent form. * Patient with caregiver is physically and mentally willing to collaborate with the investigation. * Mini-Mental State Examination (MMSE) score between 14 and 26 (inclusive) at screening Exclusion Criteria: * Evident mental disability or other limitation that prevents the patient or caregiver from administering the study evaluations. * Patients with neurological symptoms or signs that suggest another cause of dementia. * Skull trauma or recent intracranial surgery. * Known clotting disorders. * Use of anticoagulants, a medication to prevent harmful blood clots (warfarin, heparin or NOAC). * Patients where coexistence of another disease or condition that may lead to significant disability (cancer, septic embolism, endocarditis, myeloproliferative disease, creatinine\> 3 mg / dl (265µmol / L), hyperkalemia \> 5.0 mmol / L, chronic/severe liver or kidney or heart disorders. * Patients with a history of hypersensitivity to rhEPO. * Patients with known allergy to any ingredients of the product. * Patients who present nasal irritation (sneezing) or a runny nose before starting treatment. * Patients who present asthma attack at the beginning of the treatment. * Patients receiving treatment with AChE-I or Memantine who are not stable for 12-weeks prior to screening. * Patients receiving treatment with psychoactive that can compromise the clinical trial results or neuropsychological tests. * Patients with a history of alcoholism and/or drug dependence. * Patients with chronic rhinosinusitis. * Have a history of abnormal nasal or sinus symptoms. * Have prior skull fracture or abnormality (nasal defect, deviated septum). * Have recent nasal trauma (fracture in the last 2 months). * Have any prior sinus or nose surgery (rhinoplasty). * Have known bleeding problem (low platelets-thrombocytopenia), recurrent nose bleeds (\>3 year). * Have acute inflammation inside the nose. * Congenital cranial facial disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild Alzheimer'S disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Saskatchewan

    Saskatoon, Saskatchewan, S7N5E5, Canada